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Background: A better understanding of the parameters influencing vaccine-induced
IgG recognition of individual antigenic regions and their variants within the HIV Envelope
protein (Env) can help to improve design of preventive HIV vaccines.
Methods: Env-specific IgG responses were mapped in samples of the UKHVC003
Standard Group (UK003SG, n = 11 from UK) and TaMoVac01 (TMV01, n = 17 from
Tanzania) HIV vaccine trials. Both trials consisted of three immunizations with DNA,
followed by two boosts with recombinant Modified Vaccinia Virus Ankara (MVA), either
mediating secretion of gp120 (UK003SG) or the presentation of cell membrane bound
gp150 envelopes (TMV01) from infected cells, and an additional two boosts with 5
µg of CN54gp140 protein adjuvanted with glucopyranosyl lipid adjuvant (GLA). Env
immunogen sequences in UK003SG were solely based on the clade C isolate CN54,
whereas in TMV01 these were based on clades A, C, B, and CRF01AE. The peptide
microarray included 8 globally representative Env sequences, CN54gp140 and the
MVA-encoded Env immunogens from both trials, as well as additional peptide variants
for hot spots of immune recognition.
Results: After the second MVA boost, UK003SG vaccinees almost exclusively targeted
linear, non-glycosylated antigenic regions located in the inter-gp120 interface. In contrast,
TMV01 recipients most strongly targeted the V2 region and an immunodominant region
in gp41. The V3 region was frequently targeted in both trials, with a higher recognition
magnitude for diverse antigenic variants observed in the UK003SG (p < 0.0001). After
boosting with CN54gp140/GLA, the overall response magnitude increased with a more
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comparable recognition pattern of antigenic regions and variants between the two
trials. Recognition of most immunodominant regions within gp120 remained significantly
stronger in UK003SG, whereas V2-region recognition was not boosted in either group.
Conclusions: IgG recognition of linear antigenic Env regions differed between the two
trials particularly after the second MVA boost. Structural features of the MVA-encoded
immunogens, such as secreted, monomeric gp120 vs. membrane-anchored, functional
gp150, and differences in prime-boost immunogen sequence variability most probably
contributed to these differences. Prime-boosting with multivalent Env immunogens
during TMV01 did not improve variant cross-recognition of immunodominant peptide
variants in the V3 region.
Keywords: HIV, vaccine, envelope-specific antibodies, epitope variant recognition, immunogen structure,
immunogen sequence
INTRODUCTION
Development of an efficacious vaccine against the Human
Immunodeficiency Virus-1 (HIV) is complicated by high
variability of the HIV envelope glycoprotein (Env), and by the
difficulty to induce broadly cross-reactive neutralizing HIV Env-
specific antibody responses (1, 2). Vaccine-induced protection
from HIV acquisition may nonetheless be possible in the absence
of a strong HIV neutralizing antibody response; during the
Rv144 trial, high IgG levels targeting the Env hypervariable
regions 1 and 2 (V1V2) correlated with protection from HIV
acquisition (3). Subsequent studies further mapped this V1V2-
specific IgG response to a linear 15 mer peptide in the V2
region located in close proximity to the α4β7 integrin-binding
motif (4, 5). IgG responses against linear peptides covering the
highly immunogenic V3 region were also inversely correlated
with infection risk in Rv144 in a subgroup analysis (4), whereas
recognition of other, more conserved Env regions within gp120,
showed no correlation with infection risk in Rv144 (4). While
the protective mechanism of these V2- and V3- specific antibody
responses is incompletely understood, the “sieve effect” observed
in Rv144 break through infections provides solid evidence
for the protective effect of immune responses targeting these
hypervariable regions: Break through HIV strains in Rv144
vaccine recipients had specific point mutations in the targeted V2
and V3 epitopes compared to those in placebo recipients (6, 7).
High levels of vaccine-induced Env-binding antibodies—and in
particular those targeting the V2 region—also correlated with
protection from AIDS virus acquisition during a well-controlled
non-human primate study (8). Together these results emphasize
that non-neutralizing antibody responses targeting vulnerable
Env regions may mediate vaccine-induced immunity.
Properties inherent to different immunogens and vaccination
strategies are likely to determine immune recognition of a
specific region and its antigenic variants. A better understanding
of the vaccine parameters influencing IgG recognition of
different Env antigenic regions and their variants could therefore
help to improve design of preventive HIV vaccines. HIV
Envelope protein based immunogens can consist of soluble
gp120 monomer (9, 10), or gp140 trimers that may include
molecular modifications to stabilize a near-native quaternary
structure of the protein (11, 12). In addition, derivates of gp41
alone and gp120 have been used in preclinical HIV vaccine
studies (9, 13) to focus the immune response toward these
Env regions. Env-based immunogens are also often encoded in
recombinant viral, DNA/RNA vaccine vectors either as gp120,
gp140 or as membrane-anchored molecular forms of the Env
glycoprotein, such as gp160/gp150 (14) allowing expression
of the Env immunogens in vivo mimicking natural viral
infection. HIV vaccination strategies entering clinical testing
often include multiple Env immunogen variants and prime-
boost regimens that combine different vaccine vectors. These can
be administered simultaneously (15) or consecutively (16). The
immunologic consequences of such strategies have been poorly
defined and methodologies for comprehensive evaluation have
been limited so far. For instance, it is unclear whether sequence-
heterologous prime-boost vaccination strategies improve or even
worsen recognition of highly variable regions, by diluting the “net
sum” B-cell receptor stimulus for the hypervariable regions.
The UKHVC003 (UK003) and TaMoVac01 vaccine trials
investigated the immunogenicity of a recombinant, trimeric
gp140 protein (CN54gp140) in combination with different
DNA-MVA prime-boost strategies. During the UK003 trial,
vaccine recipients of the standard group (SG) first received
a DNA vaccine encoded CN54gp160 and then a secreted
form of CN54gp120 encoded in the MVA (17). In contrast,
during TMV01, vaccine recipients first received the HIVIS-DNA
vaccine that included among others three plasmids encoding
for subtypes A, C and B gp160 Env sequences and then two
boosts withMVA-CMDR-gp150, which encodes for amembrane-
anchored, CRF01_AE derived Env gp150 (16, 18). Both trials
included two final boosts with the subtype C derived, trimeric
protein CN54gp140 in glucopyranosyl lipid adjuvant (GLA) were
administered (19). In order to identify vaccine parameters that
influence vaccine-induced recognition of different Env antigenic
regions and their variants, we systematically compared the
IgG recognition of individual, linear HIV Envelope antigenic
regions between the two trials and further mapped the most
immunodominant antigenic regions to native trimeric gp160 and
monomeric gp120 protein structures.
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MATERIALS AND METHODS
Vaccinations and Volunteers
Plasma samples from adult vaccine recipients in the TaMoVac01
[TMV01, n = 17 (16)] and UKHVC Spoke 03 trials [UK003,
n = 11 (17)] were analyzed in this study. The UK003
trial was a clinical phase 1 vaccine trials. TMV01 was a
phase 2a trial. Neither of these trials tested for vaccine
efficacy. As shown in Figure 1, TMV01 and in the UK003SG
consisted of three DNA vaccinations, followed by two boosts
with a recombinant Modified Vaccinia Ankara virus and two
additional boosts with 100 µg of the recombinant subtype
C Envelope protein CN54rgp140 adjuvanted with 5 µg of
the synthetic Toll like receptor 4 agonist GLA-AF. The
recombinant CN54gp140 Env protein is an uncleaved, soluble
trimer that does not contain stabilization mutations, such as
SOSIP (16).
During the TMV01 trial, healthy volunteers from Tanzania
received seven TMV01-DNA plasmids (total amount between
0.6 and 1.0 mg/vaccination, referred to as HIVIS-DNA in
other publications) at weeks 0, 4, and 12 intradermally using
the Zetajet device. While these subjects belonged to three
different randomization groups, there was no difference in
gp160-specific IgG titer between these groups (20). Three of
the seven plasmids encoded for gp160 of HIV-1 subtypes A,
B, and C. The other four plasmids encoded for HIV-1 Rev
and Gag (subtype B), Gag (subtype A) and a mutated form
of the Reverse Transcriptase (subtype B) (21). At weeks 30
and 46, two boosts with 108 PFU HIV-MVA-CMDR-gp150,
expressing a membrane-anchored gp150 CRF01_AE, were given
intramuscularly. 12 or above weeks after the second MVA-
CMDR boost, two additional boosts of 100 µg of CN54rgp140/5
µg GLA were administered into the deltoid muscle of the
left arm.
The UK003SG included healthy volunteers from the
United Kingdom. The DNA vaccination consisted of two
DNA plasmids; one encoded (CN54gp140) Env and the other
a (ZM96) Gag-Pol-Nef fusion protein (17). Four milligrams
of each DNA plasmid was administered intramuscularly
(IM) at weeks 0, 4, and 8 followed by two IM boosts with
108 TCID50 of the MVA-C-gp120 at weeks 16 and 20 and
two additional IM boosts with 100 µg CN54gp140/5 µg
GLA-AF at weeks 24 and 28. The MVA-C-gp120 expressed a
secreted form of CN54gp120 Env and Gag-Pol-Nef polyprotein
from two back-to-back synthetic early/late transcriptional
promoters (22, 23).
The study documents for both trials were reviewed and
approved by the relevant Ethical review boards and participants
of both trials gave fully informed written consent according to
the Declaration of Helsinki before any study procedures were
conducted. The TaMoVac01 trial is registered at the World
Health Organization International Clinical Trials Registry with
registration number PACTR2010050002122368. The UKHVC
Spoke 03 trial was registered with the European Union Drug
Regulating Authorities for Clinical Trials (EUDRACT TC 2012-
003277-26) and Clinical Trials.gov (NCT01922284) and with the
UK Clinical Trials Research Network (UKRN-14173).
Peptide Array Design
The array consisted of triplicates of 2,212 immobilized 15
mer peptides. Full length Env immunogen sequences included
were, CN54gp140 (subtype C) and CMDR (subtype AE) and
8 additional sequences from acute phase primary HIV isolates
of subtypes A, C, B, CRF01_AE, and CRF02_AG to maximize
coverage of global HIV diversity. These were selected on the basis
of acute infection sequences, extracted from the Los Alamos
data base (n = 6,467). Of those, one predominant sequence
from each patient n = 350) was retained. After phylogenetic
analysis of these 350 acute infection sequences (Figure 2A), we
selected eight sequences according the geographic provenance
and to the available patient information on Fiebig stage, day
post-seroconversion and viral load to insure they were as close
from seroconversion as possible in addition to representing
the major subtypes (Figure 2A); [06.RU.SP.R163.IorII_13
(subtype A1, Russia, GU481385), Q842.d12.PNS70d.KE
(subtype A1, Kenya, AF407160), PHI374_FR (subtype
B, France, AF041133), US.1990.BORId9.2F8 (subtype B,
USA, EU576282), 25925.2.IN (subtype C, India, EF117273),
MW.2003.CHV0011210.0393.C3 (subtype C, Malawi, FJ444215),
FR.1996.PHI426 (CRF01_AE, France, AY231158) and PHI127
(CRF02_AG, France, AY231152)] (Supplementary Table 1).
Previously defined antigenic regions, frequently recognized by
vaccinees in the TaMoVac01 trial (unpublished results), RV144,
VAX003, and VAX004 (4), were covered with up to 86 additional
peptide variants in hypervariable regions. These were located in
the V2 region (peptide starting with HxB2_163), in the V3 region
[V3a (HxB2_300-324) and V3b (HxB2_349)], in the C-terminal
of V4 (HxB2_409-447), in the gp41 Immunodominant region
(HxB2_576-614) and the gp41 cytoplasmic tail (HxB2_696-730).
The relative peptide number per envelope region is given in
Figure 2B. The final peptide selection was blasted against all
published sequences from the Los Alamos data base to establish
the per peptide recognition frequency, illustrated in Figure 2C.
Linear Peptide Array Mapping
Microarrays were processed according to the manufacturers
instructions with minor modifications (www.jpt.com).
Briefly, the slides were incubated with T20 blocking buffer
(Thermofisher) for 10min. Plasma samples were then added at
a dilution of 1:100 in T20 blocking buffer, and incubated for 2 h
at room temperature with gentle shaking before washing 5 times
with 2.5ml TBS-Tween (0.5% Tween). The secondary mouse
anti-human-IgG Dylight649 (JPT) was then incubated at room
temperature for 1 h at a dilution of 1:5,000 in T20 blocking buffer.
After 5 washings with 2.5ml TBS-Tween, and 5 washes with
double distilled de-ionized water, the slides were left to dry under
a laminar flow hood. Samples from all time points from one
individual were processed simultaneously. Slides were scanned
on a GenePix 4000A scanner and processed using GenepixPro
6.0 software at 650 and 532 nm to generate a Tiff image file.
The array lay out was then added using an array-specific.gal file.
Accuracy of the array alignment was controlled, and individual
features were adjusted or excluded manually when needed
during the quality control step. Individual peptide-specific IgG
responses were then mapped after subtraction of FI values from
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FIGURE 1 | Vaccination schedules in the UKHVC003 Standard Group and TaMoVac01 trial. The UKHVC 003 SG vaccine comprised DNA plasmids (8
mg/immunization) and MVA (108 TCID50/immunization) coding for matched subtype C-derived CN54 based Env and ZM96 Gag, Pol, and Nef immunogen sequences.
Of note, MVA-C expressed only the gp120 portion of Env. The CN54rgp140 protein (100 ug/immunization) was adjuvanted with 5ug GLA-AF and administered as two
additional boosts. The TaMoVac I vaccination regimen included DNA vaccination (600 or 1,000 µg/immunization) with 7 plasmids (encoding for Env subtypes A, B,
and C and Rev subtype B as well as Gag subtypes A, B, and RTmut subtype B) delivered intradermal, followed by MVA-CMDR (108 pfu/immunization), expressing
HIV gp150 (subtype E), Gag and Pol (subtype A), and two additional boosts with 100 µg of CN54rgp140 protein adjuvanted with 5 µg GLA-AF.
baseline plasma. Positive responses were defined as equal or
above 2,500 fluorescence intensity units after subtraction of the
pre-vaccination value.
R Script Based Analyses of Peptide Variant
Recognition by IgG in the Context of
Peptide Sequence Phylogeny and
Frequency of Occurrence
A R-script was developed to visualize the magnitude of the
IgG recognition of peptide variants of a given antigenic region,
and linking these data to the phylogenetic relationship of these
sequences as well as the frequency of their occurrence in the
database. Our script utilizes the R package GGTREE by Yu
et al. as a base (27). The new script uses the existing newik and
fasta files and combines them within a single step into a new
form of result visualization in the context of the magnitude of
IgG recognition (color coded) and the frequency of occurrence
(coded by icon size, HIV database) of a given peptide variant.
For our analyses, a maximum likelihood phylogenetic tree for
36 antigenic variants of the HIV V3 Tip region (HxB304)
was generated after sequence of 75 amino acids was added
as scaffolding to each of the 15 mer peptides. The tree file
was then converted to a newik file for input into the R-
script analyses. To interrogate the frequency of variant sequence
occurrence, more than 3,500 representative HIV primary isolate
whole length Envelope sequences were selected from the global
HIV sequence database (www.hiv.lanl.gov) using following
parameters: uniqueness, one sequence per patient and an overall
good representation of the global HIV epidemic and saved as
a fasta file. The subtype distribution and numbers of subtype-
specific sequences in these selected sequences were as follows:
subtype B (n = 1,459), subtype C (n = 969), CRF01_AE (n
= 419), subtype A (n = 205), recombinant molecular forms of
subtype B and C (n = 156), recombinant molecular forms of
subtypes A other than CRF02_AG (n= 138), all other molecular
forms combined (n= 340).
RESULTS
Basic Demographics of Subjects Included
in the Peptide Array Analyses
Analyzed TMV01 vaccine recipients (n = 17) were all black
Africans, had a median age of 29 years (range 18–38) and
included 7 females. The 11 vaccine recipients from UK003SG
included in the analyses (all made available for peptide array
mapping) were all white Europeans and had a median age of 36
years (range 20–44) and included 5 females.
IgG Recognition of Linear Antigenic
Regions Envelope After the Second
MVA Boost
Four weeks after the second MVA boost, we observed profound
differences in the antigenic regions targeted by the Env-
specific IgG response between UK003SG and TMV01 (Figure 3;
Table 1). In total, 8 immunodominant regions (IDR, defined
by a frequency of responders (FOR) of >50%, numbered black
balls in Figure 3) were detected considering both trials. For
7 of these 8 regions the magnitude of peptide recognition
(Mean Fluorescence Intensity (MFI) of all tested peptides for
a given region) differed significantly between UK003SG and
TMV01 vaccine recipients (all p < 0.01, Table 1, Figures 4A–H).
Recipients of the UK003SG regimen exclusively targeted
antigenic regions located within gp120, including the constant
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FIGURE 2 | Peptide array design to cover recently transmitted global HIV strains. (A) Phylogenetic analysis of acute infection sequences (n = 350) from the Los
Alamos database used for the selection of the eight isolates (in red) to design the peptide array. Purple diamonds indicate the isolates of the vaccine immunogens
CMDR and CN54. Evolutionary analyses were conducted in MEGA6 (24) and the evolutionary history was inferred using the Neighbor-Joining method (25). The
percentage of replicate trees (Bootstrap test 100 replicates) in which the associated taxa clustered together is shown above the branches (26). (B) Number of 15-mer
amino acid (aa) sequences represented in the peptide array. The peptide array was aligned to the HxB2 sequence that was scanned with a sliding window of 11 aa
using a three aa step. The Y-axis indicates the number of 11-mer aa sequences found in the array corresponding to a given 11-mer HxB2 window. (C) Peptide
recognition amongst the known Los Alamos database HIV-1 sequences. 2,078 peptides produced 471,597 complete homology hits amongst 10,956 virus isolates.
The Y-axis indicates the number of hits per peptide position, each subtype represented by a different color.
region (C) 1 [starting at amino acid (aa) positions 112 (IDR1,
Mean Fluorescence Intensity (MFI): 25,412)], in the C2 region
(aa221, IDR3, MFI: 7,702, and aa270, IDR4, MFI: 8,176) and
two regions in C5 (aa503, IDR6, MFI: 10,800, and aa491 (IDR7,
MFI: 4,540). Corresponding HxB2 locations are provided in
Table 1. None of these regions were recognized by more than
2 of 17 TMV01 vaccine recipients. Participants in both trials
targeted the V3 loop tip (IDR5, aa322–326), but we observed a
5-fold higher MFI for the UK003SG as compared to for TMV01
vaccine recipients. In contrast to UK003SG, TMV01 vaccine
recipients frequently targeted the V2 loop (IDR2—aa163, MFI:
4,300, p = 0.003) and an immunodominant region within gp41
(IDR8—aa608, MFI: 2,336, p = 0.005). Of note, gp41 was not
contained in MVA-C-gp120 used in UK003SG. Considering all
gp160 regions that were targeted by at least 25% of vaccine
recipients in either trial [UK003SG (38 regions) as compared
to TM01 vaccine recipients (30 regions)], mean magnitudes for
IgG recognition of antigenic regions was higher in UK003SG as
compared to TMV01 (mean MFI: 17,823 vs. 7,791, p < 0.0001,
data not shown). Similarly, considering only IgG recognition of
gp120, a 2.2-fold broader response was detected in UKHVC003S
vaccine recipients (38 vs. 17 regions targeted by ≥25% of
vaccine recipients, Figure 4I) and individual region-specific IgG
responses had higher mean magnitudes in UK003S as compared
to TM01 vaccine recipients (mean MFI: 17,823 vs. 7,410,
p = 0.0003). Together these data demonstrate that the largely
sequence homologous UK003SG regimen induced a stronger and
broader IgG response, with little overlap in frequently recognized
Env regions after the second MVA boost as compared to the
sequence heterologous TM01 regimen.
IgG Recognition of Linear Antigenic Env
Regions After the Second Immunization
Boost With CN54gp140/GLA
The pattern of Env recognition still differed between the two
groups at 4 weeks post-final vaccination with the second
CN54gp140/GLA. Mean magnitude of recognition was still
Frontiers in Immunology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 717
Nadai et al. Vaccine-Induced HIV-Env-Specific IgG Epitope Recognition
FIGURE 3 | Mapping of antigenic regions targeted by Env-specific IgG responses in UKHVC003 and TaMoVac01. The frequency of responders (FOR, y-axis) to
antigenic regions within the Envelope protein (A) after the second MVA (first row) and after CN54rgp140/GLA boosts (second row) is shown for the UKHVC_003
standard group (left panels, n = 11), and for TaMoVac01 recipients (right panels, n = 17). Immunodominant regions 1–8 are indicated. For region-specific IgG
responses occurring in at least 25% of vaccinees, the mean fluorescence intensity (MFI) is shown in (B) after MVA (third row) and after CN54rgp140/GLA boosts
(fourth row) for the two groups. IgG responses against individual antigenic regions were considered positive, if the corresponding fluorescence intensity was above
2,500 after subtraction of the pre-vaccination value. Mapping results from UKHVC003 were partially published previously (17).
TABLE 1 | Selected frequently recognized HIV Envelope regions and their recognition after the second MVA and after the second CN54gp140 vaccination.
Post-MVA#2-MFI of all subjects Post-CN54gp140#2-MFI of all subjects
IDR aa Representative sequence HxB2 Env. region UK003 SG TMV01 p-Value UK003 SG TMV01 p-Value
1 112 DIISLWDQSLKPCVK 107–121 C1 25,412 1,936 <0.0001 36,822 3,384 0.0004
2 176 ELRDKKQKVHALFYK 163–177 V2 1,604 4,300 0.0029 1,848 3,681 0.0530
3 221 AITQACPKVTFDPIP 200–214 C2 7,702 1,855 0.0024 13,108 3,565 0.0220
4 270 HGIKPVVSTQLLLNG 249–263 C2 8,176 1,692 0.0004 10,033 1,805 0.0006
5.1 322 NNTRKSIRIGPGQTF 301–315 V3 Tip 11,403 2,193 <0.0001 19,514 6,852 0.0005
5.2 325 RKSIRIGPGSTFYAT 304–319 V3 Tip 28,606 5,669 <0.0001 38,003 25,618 0.0126
6 503 GDMRNNWRSELYKYK 473–487 V5C5 10,800 3,902 0.0041 30,591 7,271 0.0035
7 521 IKPLGVAPTTTKRRV 491–505 C-term gp120 4,540 2,684 0.0590 16,193 7,044 0.0058
8 608 LQARVLAVERYLKDQ 576–591 gp41 1,104 2,336 0.0049 1,544 20,221 <0.0001
significantly higher in UKHVC_003 vaccinees in 6 of 8
IDR regions (Table 1; Figures 4A–H) and the magnitude of
recognition still differed significantly for the same IDRs as after
the second MVA boost (p < 0.05). However, more TMV01
vaccine recipients were now also recognizing most of the 8 IDRs
including the V3 region and other more conserved antigenic
regions within gp120. Of note, there was no measurable effect
of the CN54gp140 protein boost on IgG recognition of the V2
loop in either group. Three N-terminal antigenic regions in C1 of
gp120 (HxB74, 104–109, 117–121, Figure 3) were still recognized
exclusively by UKHVC_003 participants. Consecutive peptides
covering the tip of the V3 region (located at HxB aa312–315)
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FIGURE 4 | Comparison of IgG responses targeting selected frequently recognized regions in UK003SG or TMV01. Shown is for the eight selected immunodominant
regions [IDR1-8 (A–H)] for each analyzed vaccinee the mean recognition MFI over all tested antigenic variants at baseline, after the second boost with MVA and after
the second boost with CN54gp140/GLA. The first HxB aa position of the 15 mer peptide and number of tested variants are indicated for each antigenic region. The
mean MFI of responses for each antigenic region recognized within gp120 by above 25% of vaccinees are shown in (I). The results of the statistical analyses by
Mann-Whitey test comparing data from the two trials are indicated only for (I). Data points from UK003SG and TMV01 are shown in magenta and light blue,
respectively. The statistical analyses for differences in mean recognition magnitude for (A–H) is provided in Table 1.
were targeted by>90% vaccinees with a highMFI, of max. 38,003
and 25,618 in UK003SG and TMV01, respectively. Interestingly,
recognition of the IDR8, covering part of the immunodominant
region of gp41, was boosted by CN54rgp140 administration in
TMV01 participants, while this region was not being recognized
to detectable levels in UK003SG (p < 0.0001). This suggests
that although CN54gp140 contains the extracellular domain of
gp41, the region-specific immunogenicity was not sufficient to
mount substantial levels of gp41 specific ABs in the absence of
MVAmediated priming. Considering all antigenic regions within
gp120, a broader Env-specific IgG response was detected after
the second CN54gp140/GLA boosts in vaccine recipients of both
trials. UK003SG recipients had a 2.6-fold broader recognition (68
vs. 26 regions targeted by ≥25% of vaccine recipients) compared
to TMV01 (Figure 4B). Individual region-specific IgG responses
had higher mean magnitudes in UK003SG as compared to TM01
vaccine recipients.
Assessment of Immunogen Sequences,
Protein Structure and Glycan Profiles in the
Eight Most Immunodominant Regions
Differences in the Env immunogen sequences during the prime-
boost vaccinations might have contributed to the differences
observed here in vaccine-induced IgG recognition of HIV Env.
Figure 5 shows an alignment of the immunogen sequences for
each of the 8 immunodominant antigenic regions. UK003SG
participants received CN54 based immunogen sequences that
were identical in gp120 but deleted of gp41 in the MVA-C-
gp120. The TMV01 vaccination contained much more diverse
Env immunogen sequences for most of the IDRs. The IDR
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FIGURE 5 | Alignment of immunogen sequences for the eight selected immunodominant antigenic regions for immunogens included in TMV01 and UK003SG. From
top to bottom; the first row indicates the Immunodominant region, HxB2 location and Region name and shows a representative sequence for this region. Row 2–4
show three sequence variants of the TMV01-DNA encoded Env proteins representing subtypes A, B, and C, respectively. Row 5 shows the MVA-CMDR-gp150
encoded subtype E sequence that was used during TMV01. Row 6 shows the CN54 sequence, which matches the DNA and MVA-C-gp120 encoded Env
immunogens of UK003SG and the CN54gp140 recombinant protein administered in both trials.
8 within gp41 region was included by the TMV01-DNA
gp160 encoding plasmids, MVA-CMDR-gp150 and in the
CN54gp140 boost.
Protein structural and conformational aspects as well as
glycosylation patterns might also influence the magnitude of IgG
recognition of individual Env regions. Figure 6 shows the 8 IDRs
as color coded solvent accessible surface areas (SASA) on a native
trimeric Env protein structure (here: stabilized C-clade consensus
structure (28) and in a gp120 structure in the CD4 induced state
[HXBc2 gp120 core structure (29)] as this is a possible alternative
conformation present in vivo during immunizations.
In this well-ordered trimer structure IDR2 (V2) and IDR5
(V3) are oriented toward the trimer apex. Most of other IDRs are
either located in the inter-gp120 interface in the direction of the
trimer axis [IDR1 (C1), IDR3 (C2)], at the gp41-gp120interface
(IDR7) located in gp41 in the direction of the trimer axis (IDR8)
(compare Figure 6B). IDR4 and IDR6 are located in the core
of gp120, mostly buried under the outer domain. Hence, in a
well-ordered trimer structure, the majority of these epitopes are
potentially concealed from antibody recognition. In contrast the
context of gp120 (Figure 6C) most of the gp120 IDRs are well-
accessible except IDR4 and IDR6, which are still buried in the
protein core.
We next analyzed glycosylation sequence motifs of the 8 most
immunodominant regions using the HIV sequence compendium
2015—HIV-1 proteins (Table 2). Six of the eight IDRs did not
contain any glycosylation motif. IDR4 ended in such a motif
and IDR5.1 (V3) started with such a motif. Glycosylation motifs
were located in very close vicinity (≤5 aa) upstream of 5
IDRs. Glycosylation motifs downstream were located in varying
distance (0 to >20 aa). Together our results suggest that non-
glycosylated Env regions located at the Envelope tip (V2 and V3)
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FIGURE 6 | Mapping of immunodominant peptide regions (IDR) to the structure of Env. (A) Color-coded solvent accessible surface area (SASA) of the eight IDRs
projected on a native like Env trimer (C-clade consensus structure, PDB ID 8ck9). Glycans were removed and IDRs are highlighted in all protomers. Both IDR5.1 and
IDR5.2 are combined as IDR5. (B) Eight IDRs projected onto the surface of a gp120-gp41 protomer from (A). (C) Location of the IDRs in the context of a
CD4-induced (CD4i) gp120 structure (PDB ID 3jwd). Variable loops 1–4 which are deleted or not resolved in the structure are symbolized by dotted lines.
or in the inter-gp120-interface are the most immunodominant
regions of gp120 as detected by linear peptide array analyses.
Comparison of Antigen Variant
Recognition Within V3 and V2
The V3 region was among the most immunodominant regions
in gp120 after the CN54gp140 protein boost in both vaccine
trials with particularly strong recognition of the V3-tip region
(HxB2 aa position 301–320). Cross-recognition of the V3-
tip region was assessed with >35 antigenic variants for
each of the overlapping peptide regions HxB301–316 and
HxB304–318. In the UKHVC003SG, strong IgG recognition of
many different antigenic variants of the V3 tip was already
detected after the two MVA-CN54gp120 boosts (Figure 7A,
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TABLE 2 | Analyses of Envelope protein glycosylation motifs within or near frequently recognized immunodominant regions.
Glycosylation motifs
IDR Representative sequence HxB2 Env. region Inside region Downstream (N-terminal) Upstream C-terminal Other comments
1 DIISLWDQSLKPCVK 107–121 C1 None 16 aa 10 aa 2 aa from CD4 BS residue
2 ELRDKKQKVHALFYK 163–177 V2 None 2 aa 5 aa –
3 AITQACPKVTFDPIP 200–214 C2 None 1 aa 14 aa –
4 HGIKPVVSTQLLLNG 249–263 C2 C-terminal 5 aa –
5.1 NNTRKSIRIGPGQTF 301–315 V3 Tip N-terminal 13 aa –
5.2 RKSIRIGPGSTFYAT 304–319 V3 Tip None 2 aa 17 aa –
6 GDMRNNWRSELYKYK 473–487 V5C5 None 7 aa >20 aa Contains CD4BS residues
7 IKPLGVAPTTTKRRV 491–505 C-term gp120 None 5 aa >20 aa 6 aa from gp120 C-term
8 LQARVLAVERYLKDQ 576–591 gp41 None >20 aa 20 aa Ends in gp41 IDR
not shown for HxB301–316), whereas IgG recognition was
much weaker after the two MVA-CMDR-gp150 boosts in the
TMV01 trial (Figure 7B). The numeric MFI data for V3
peptide variant recognition shown on the phylogenetic heat map
trees are provided in Supplementary Table 2. Of note, relative
recognition of the same peptide variant after the two MVA
boosts was quite similar between both trials. One example, V3-
tip sequence variants RKSIRIGPGQTFYAT (CN54 sequence,
arrow in Figure 7) and the related RKSVRIGPGQTFYAT
were recognized in both trials. Both of these sequence
variants are overrepresented in the HIV sequence database.
The most notable difference between the two trials is 1.)
the much higher magnitude of recognition for almost all
recognized V3 tip variants in the UKHVC003 trial and
2.) the comparatively good recognition of the two related
peptide variants RKSIPIGPGRAFY(A/T)T upon MVA-CMDR
vaccination in TMV01 participants, with a proline in position 5,
which is also contained in the immunogen CMDR sequence. In
summary these results show that the use of diverse immunogen
sequences in prime and boost during the TMV01 trial was
not associated with better cross-recognition of V3-tip variants
as compared to the use of a single V3 immunogen sequence
during UKHVC03.
By contrast, the V2 region was targeted exclusively by
TaMoVac 01 vaccinees, in which V2-specific responses peaked
after the second MVA-CMDR. The response was focused
on a single peptide region (HxB163/164) without measurable
recognition of the adjacent overlapping regions. Out of the
86 variants tested, <10 sequence variants were recognized
well by the majority of TMV01 vaccinees after the second
MVA-CMDR (Supplementary Figure 1). The numeric MFI data
for V2 peptide variant recognition shown on the phylogenetic
heat map trees are provided in Supplementary Table 3. Most of
the well-recognized variants were closely related to the MVA-
CMDR-gp150 encoded immunogen sequence (≤2 mutations).
Administration of CN54gp140/GLA did not boost these
responses (data not shown). Both TMV01-DNA encoded Env
during TMV01 as well as the CN54 immunogen sequences have
4–7 aa mismatches in this 15 mer region compared to the MVA-
CMDR sequence (Figure 5), raising the question whether the
DNA vaccine primed this V2-specific response.
DISCUSSION
A better understanding of vaccine parameters influencing IgG
recognition of individual Env regions and their antigenic variants
can contribute to rational HIV vaccine design. Using a linear
peptide array approach, we compared Env-specific IgG responses
in two clinical trials, which tested different DNA prime MVA
boost vaccine combinations followed by additional boosting with
the same recombinant, trimeric CN54gp140 protein. All Env
immunogen sequences in UK003SG were derived from HIV
subtype C isolate CN54 including a MVA vector encoding for a
secreted molecular form of gp120 (17). In contrast, TMV01, Env
immunogen sequences were multivalent and included a MVA
vector encoding for a membrane-anchored, functional molecular
form of gp150 (18). The functionality of this gp150 protein has
been determined by its capacity for induction CD4- and CCR5-
dependent cell fusion in vitro (18). The two groups also differed
in the exact timing of immunogen administrations, the route and
amount of DNA administration, trial location and ethnicity/race
of participants. While we consider it unlikely, we cannot exclude
the possibility that some of these differences may also have
influenced the pattern of Env-specific linear epitope recognition
by IgG. Here, we focus the discussion on the potential impact of
immunogen sequence variability and structure on the pattern of
vaccination-induced Env-specific IgG recognition.
The pattern of Env epitope recognition detected UK003SG
after the MVA boosts, shared many features with those described
previously for vaccine trials Rv144, Vax003 and Vax004 (4).
The IDR1 (HxB104) was frequently recognized in UK003SG
recipients, Rv144 and Vax003 (“C1a”) and to a lesser degree in
Vax004. UK003SG and Vax003 recipients frequently recognized
C1b (HxB120). Further, similar regions in V3 and C5 were
recognized in UK003SG after the MVA-C-gp120 boosts and after
final vaccination in Rv144, Vax003 and Vax004, which were all
based on gp120 monomeric Env. Some of these targeted regions
differ from those targeted during natural HIV-1 infection [(4)
and unpublished observation], and significantly differed from
those frequently targeted after the MVA-CMDR-gp150 boosts
in TMV01. The usage of gp120-based immunogens in these
trials may therefore induce a different Env recognition pattern as
compared to the membrane-bound, functional Envelope protein
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FIGURE 7 | Phylogenetic heat map analyses of IgG recognition of the Env variable region 3 in UK003SG and TMV01 vaccine recipients. Shown is a heat map of mean
signal intensities of IgG recognition of 36 peptide sequence variants of the variable region 3 tip (HxB304_ RKSIRIGPGSTFYAT) in the context of their phylogenetic
relationship and their frequency of occurrence in the HIV database represented by the icon size. (A,B) Show the results after the second MVA boost, (C,D) for the
results after the second CN54gp140/GLA boost with the vaccine. A maximum likelihood phylogenetic tree for 36 antigenic variants of the HIV V3 Tip region was
generated after sequence of 75 amino acids was added as scaffolding to each of the 15 mer peptides represented on the peptide array. Please note the different heat
map scale in (B). The arrows point to the CN54 isolate sequence in the respective trees.
encoded in the MVA-CMDR-gp150. Indeed, the induction
of Abs binding to Env epitopes located in the inter-gp120
interface that may be structurally shielded in a native trimer
might be direct consequence of soluble gp120 secreted from
cells infected with HIV-MVA-gp120 (UK003SG), where these
regions are readily accessible to antibodies (compare Figure 6).
While speculative, such structural and steric features may also
explain why targeting of these epitopes within the relatively
conserved inter-gp120 interface was not associated with immune
protection during previous efficiency trials Rv144, Vax003, or
Vax004 (4).
The magnitude of recognition of most gp120 IDRs was
comparatively weak in the TMV01 participants, which contrasted
the strong recognition of these regions in UK003SG. The
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comparatively low degree of sequence conservation between
prime and boosts might also have contributed to this pattern;
sequence conservation is 100% for UK003SG and always less
for TMV01 vaccine regimen. IDR1 (“C1a”) or IDR7 (“C5a”)
sequences however were well-conserved between the TMV01
DNA and MVA immunogens. Non-recognition after the MVA
boosts of these regions can therefore not be explained by
sequence differences in the TMV01 immunogen composition.
As mentioned above, the encoded immunogens of MVA-CMDR-
gp150 and the MVA-C-gp120 differ significantly in structural
features that are relevant for epitope accessibility to antibodies;
particularly IDR7 (“C5a”) is in spatial proximity with gp41 and
contains amino acids in direct contact to gp41 (29). Hence,
IDR7 may be accessible only on gp120 based immunogens, but
much less so on the membrane-anchored, functionally intact Env
protein encoded by MVA-CMDR-gp150. As shown in Figure 6,
IDR7/C5a is most probably occluded on the functional trimer
and on soluble trimers made of SOSIP gp140 (11, 29, 30).
However, CN54gp140 vaccination boosted IDR7/C5a-specific
IgG responses in UK003SG, while repetitive vaccination with
CN54gp140 protein alone only induced weak recognition of
C5a (31). Negative-stain electron microscopy analyses suggested
that CN54gp140 is an aberrant trimer with partial disintegration
into gp120 and gp41-ectodomains (12). Hence, C5a may be
partially accessible on the CN54gp140 immunogen. Besides
structural occlusion and sequence characteristics, glycosylation
of epitopes may abrogate recognition of the corresponding
non-glycosylated peptides. Roughly 90 N-linked glycans−28 per
protomer—shield the protein surface of native, trimeric Env from
immune recognition. N-linked glycan compositions have been
characterized quite detailed and mapped to the trimeric Env
protein structure previously (32, 33). Almost all detected IDRs
in this study did not contain such glycosylation motifs, except
for two IDRs, which start started or ended in such a motif
(IDR5.1, IDR4). Close vicinity to glycosylated sites was therefore
not abrogating IgG recognition of IDRs in our study. High glycan
shielding of the outer trimer surface and/or missing glycans in
the peptide array might be a reason for its comparatively lower
immunogeneicity and/or low reactivity of the corresponding
non-glycosylated peptides in the micro array assay. Interestingly,
recombinant, monomeric gp120 has increased levels of N-linked
complex-type glycans, but decreased glycan occupancy in 10
of the 24 sites compared to trimeric molecular forms of Env
(33). It is one important limitation of current peptide array
approaches that these do not allow to interrogate the influence
of natural N-linked glycans on linear epitope recognition by
binding antibodies. Incorporation of natural Env glycosylation
in synthetic peptide arrays would therefore be useful to better
define their influence on linear epitope recognition. In follow-up
libraries this could be considered [e.g., for N-linked (GlcNAc. . . )
at Asn residues]. However, limited availability of such building
blocks and high cost hamper a comprehensive characterization
of the influence of glycosylation on antibody recognition during
peptide array analyses. In summary, sequence-, structural-, and
glycan related differences between Env immunogens used in
UK003 and TMV01 most likely have contributed to differences
in IgG recognition profile.
The IDR8 recognition in gp41 was absent in UK003SG
recipients due to the lack of gp41 in the MVA-C-gp120 vector.
IDR8 recognition was still absent after the CN54gp140/GLA
boost in UK003SG, but present in TMV01 after MVA-CMDR-
gp150 and further boosted by CN54gp140/GLA. While we
consider it unlikely, it is still possible that the inclusion of the
gp41 IDR region present in the MVA-CMDR-gp150 encoded
immunogen “deviated” IgG responses away from gp120 regions.
Future studies need to address the hypothesis of possible
“deviation” for vaccine induced IgG responses.
A high proportion of TMV01 recipients upon the MVA-
CMDR-gp150 boosts recognized the identical V2 epitope that
was correlated with protection from HIV-acquisition in the
Rv144 trial (4, 5). There was no evidence that CN54gp140/GLA
could boost this response in TMV01 recipients. The great V2
epitope sequence diversity between the MVA-CMDR-gp150 and
CN54gp140 immunogen sequences may have contributed to
this lack of boosting effect on an existing V2-epitope-specific
IgG response in TMV01 vaccine recipients. Recognition of
this epitope was however also completely absent in UK003SG
recipients immunized exclusively with CN54 based immunogens
in DNA, MVA and the CN54gp140 protein boost. Together
these observations support the hypothesis that both, structural
and sequence determinants inherent to the CMDR immunogen,
but not present in the CN54 Env immunogens, contributed to
the recognition of this V2 epitope in MVA-CMDR recipients.
Interestingly, we also were unable to detect such V2-epitope
specific IgG responses in most Tanzanian HIV seroconverters
within 2 years of infection with subtype A and Cmolecular forms
of the virus, suggesting that this response is fairly uncommon
during early natural infections (unpublished data). Rv144 and
Vax003 share the induction of this V2 epitope recognition with
TMV01 recipients. However, only 10 of 91 tested V2 peptide
variants were recognized at moderate strength in TMV01, which
appears less cross-reactive as what was reported from Rv144 and
Vax003 (4). In TMV01 recipients, recognized V2 peptide variants
were identical or close to the CMDR immunogen sequence and—
similar to what was reported for Vax003 and RV144—had a K in
the position 169, which demonstrated a sieve effect in Rv144 (6).
It is noteworthy that V2 epitope sequences are identical between
MVA-CMDR, the Rv144 immunogens ALVAC-HIV and the
recombinant AIDSVAX E (34). Hence, differences in V2 cross-
recognition between our study and the study by Gottardo et al.
(4) may be either linked to the boosting effect of the AIDSVAX
recombinant protein boosts and/or to differences in the analysis
pipeline applied. In addition, assessing vaccine-induced V2
recognition using V1V2-scaffold antigens of different clades
appears to be more sensitive as compared to the linear peptide
array approach taken here (5) and the comparatively poor cross-
recognition reported here may therefore be underestimate true
cross-recognition of the V2 region in TMV01. In summary,
V2 recognition in TMV01, Vax003 and Rv144 was most likely
induced by an identical immunogen sequences in V2. Both,
gp120- and gp150-membrane anchored molecular, as well as
both MVA-encoded (TMV01) and recombinant gp120 forms
(AIDSVAXAE in Vax003) can therefore induce this V2 response.
Hence, recognition of this V2 region in TMV01 recipients is
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probably more related to immunogen sequence and V2 structural
information embedded in the primary aa sequence, and less
related to the presence of the near native structure of Env
encoded by MVA-CMDR (18).
The CN54gp140 protein boosted recognition of the V3
hypervariable region and further improved variant cross-
recognition particularly in TMV01. It also had a measurable
boosting effect in UKHVC03SG, where V3-specific recognition
was already high after the MVA-C-gp120 boosts. The sequence
homologous prime-boost regimen UK003SG induced better
recognition of diverse variants of the V3 region as compared
to the sequence heterologous TMV01 prime-boost regimen.
This suggests that priming with heterologous Env immunogens
does not necessarily improve variant recognition in the V3
region and rather argues against priming with a hypervariable
immunogen in order to increase the depth of antigen variant
recognition. While speculative, it might therefore be possible
to improve IgG recognition of the V2 epitope variants
by using more similar prime-boost vaccination regimens
for V2.
In conclusion, the pattern of IgG recognition of individual
linear antigenic regions in Env observed in these two trials
overlapped with those in other trials and mostly targeted non-
glycosylated regions of the inter-gp120 interface. Our results
argue in favor of the hypothesis that structural differences
between the MVA encoded Env immunogens—secreted
gp120 vs. “native-like,” functional, cell membrane anchored
gp150—as well as immunogen sequence differences during
the prime-boost vaccination (monovalent vs. multivalent)
contributed to this pattern. There was no evidence
that prime-boosting with highly variable immunogens
improved cross-recognition of linear antigenic variants in
this study.
ETHICS STATEMENT
The study documents for both trials were reviewed and
approved by the relevant Ethical review boards [TaMoVac01:
Institutional review boards of the Muhimbili University of
Health and Allied Sciences, the Mbeya Medical Research
Ethics Committee, the Tanzanian National Health Research
Ethics Committee; UKHVC_Spoke03: NRES London—West
London and GTAC Ethics Committee (13/LO/0115)]. The
retrospective epitope mapping of IgG antibody responses within
both trials was further approved by the Ethics comitee of the
Ludwig-Maximilians-University of Munich. Participants of
both trials gave fully informed written consent according to
the Declaration of Helsinki before any study procedures were
conducted. The TaMoVac01 trial is registered at the World
Health Organization International Clinical Trials Registry
with registration number PACTR2010050002122368. The
UKHVC Spoke 03 trial was registered with the European
Union Drug Regulating Authorities for Clinical Trials
(EUDRACT TC 2012-003277-26) and Clinical Trials.gov
(NCT01922284) and with the UK Clinical Trials Research
Network (UKRN-14173).
AUTHOR CONTRIBUTIONS
YN, KH, and MA performed laboratory work, contributed
to data analyses, and manuscript writing. SJ, AK, and ES
contributed to clinical trials study coordination and manuscript
writing. MM, AB, AJ, SM, AC, RT, RS, MR, MH, LM,
MB, and JW contributed to the clinical trials studies. VH
and UR contributed to designing R scripts for peptide array
data analyses. JZ contributed to design and manufacturing
of peptide microarrays. DP and RW contributed to the
analyses and interpretation of peptide array data in the
context of immunogen structure and to manuscript writing.
GP contributed to peptide array design, phylogenetic sequence
and data analyses and to manuscript writing. CG conceived the
study, contributed to data analyses and interpretation and to
manuscript writing.
FUNDING
Peptide array mapping analyses was funded by the
EHVA (EC Horizon 2020, grant number 681032) and the
German Center for Infection Research (DZIF). Financial
support for the TaMoVac01 vaccine trial was received
from the European and Developing Countries Clinical
Trials Partnership (EDCTP) for two grants (Grant ID
CT.2006.33111.007 and CT.2006.33111.001) and the
German Ministry of Education and Research (BMBF, Grant
ID: 01KA0802). The UKHVC Spoke03 study was funded
through core funding from the Wellcome Trust via UKHVC
(083844/Z/07/Z), MRC (G1001784), Imperial NIHR BRC,
and NIH. YN was supported by a DZIF scholarship for MD
thesis studies.
ACKNOWLEDGMENTS
The authors would like to thank the clinical trial participants.
Mapping results from UKHVC003 were partially published
previously (17).
SUPPLEMENTARY MATERIAL




1. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC.
Antibodies in HIV-1 vaccine development and therapy. Science. (2013)
341:1199–204. doi: 10.1126/science.1241144
2. Haynes BF, Mascola JR. The quest for an antibody-based HIV vaccine.
Immunol Rev. (2017) 275:5–10. doi: 10.1111/imr.12517
3. Haynes BF, Gilbert PB, Mcelrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM,
et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J
Med. (2012) 366:1275–86. doi: 10.1056/NEJMoa1113425
Frontiers in Immunology | www.frontiersin.org 13 April 2019 | Volume 10 | Article 717
Nadai et al. Vaccine-Induced HIV-Env-Specific IgG Epitope Recognition
4. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, et al.
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120
correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
PLoS ONE. (2013) 8:e75665. doi: 10.1371/journal.pone.0075665
5. Zolla-Pazner S, Decamp A, Gilbert PB, Williams C, Yates NL, Williams WT,
et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1
subtypes correlate with decreased risk of HIV-1 infection. PLoS ONE. (2014)
9:e87572. doi: 10.1371/journal.pone.0087572
6. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T,
et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures
in Env V2. Nature. (2012) 490:417–20. doi: 10.1038/nature11519
7. Zolla-Pazner S, Williams C, Rolland M, Edlefsen PT, Kong XP, Nadas A,
et al. (2014). “The specificity of V3 antibodies in RV144 plasma implicated
in reducing HIV infection,” in CROI (Boston, MA).
8. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine
protection against acquisition of neutralization-resistant SIV challenges in
rhesus monkeys. Nature. (2012) 482:89–93. doi: 10.1038/nature10766
9. Adis International Ltd. HIV gp120 vaccine–VaxGen: AIDSVAX, AIDSVAX
B/B, AIDSVAX B/E, HIV gp120 vaccine–Genentech, HIV gp120 vaccine
AIDSVAX–VaxGen, HIV vaccine AIDSVAX–VaxGen. Drugs R D. (2003)
4:249–53. doi: 10.2165/00126839-200304040-00007
10. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris
R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection
in Thailand.N Engl J Med. (2009) 361:2209–20. doi: 10.1056/NEJMoa0908492
11. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al.
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. (2013)
342:1477–83. doi: 10.1126/science.1245625
12. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, et al. Cleavage
strongly influences whether soluble HIV-1 envelope glycoprotein trimers
adopt a native-like conformation. Proc Natl Acad Sci USA. (2013) 110:18256–
61. doi: 10.1073/pnas.1314351110
13. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al.
Immunization with HIV-1 gp41 subunit virosomes induces mucosal
antibodies protecting nonhuman primates against vaginal SHIV challenges.
Immunity. (2011) 34:269–80. doi: 10.1016/j.immuni.2011.01.015
14. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature.
(2008) 455:613–9. doi: 10.1038/nature07352
15. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A
phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant
adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV
172). J Infect Dis. (2010) 201:600–7. doi: 10.1086/650299
16. Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S,
et al. Boosting with subtype C CN54rgp140 protein adjuvanted with
glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA
is safe and enhances immune responses: a phase I trial. PLoS ONE. (2016)
11:e0155702. doi: 10.1371/journal.pone.0155702
17. Joseph S, Quinn K, Greenwood A, Cope AV, Mckay PF, Hayes PJ, et al. A
comparative phase I study of combination, homologous subtype-C DNA,
MVA, and Env gp140 Protein/adjuvant HIV vaccines in two immunization
regimes. Front Immunol. (2017) 8:149. doi: 10.3389/fimmu.2017.00149
18. Earl PL, Cotter C, Moss B, Vancott T, Currier J, Eller LA, et al. Design and
evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. (2009)
27:5885–95. doi: 10.1016/j.vaccine.2009.07.039
19. Graf M, Shao Y, Zhao Q, Seidl T, Kostler J, Wolf H, et al. Cloning and
characterization of a virtually full-length HIV type 1 genome from a subtype
B
′
-Thai strain representing the most prevalent B-clade isolate in China. AIDS
Res Hum Retroviruses. (1998) 14:285–8. doi: 10.1089/aid.1998.14.285
20. Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P,
et al. Priming with a simplified intradermal HIV-1 DNA vaccine regimen
followed by boosting with recombinant HIV-1 MVA vaccine is safe and
immunogenic: a phase IIa randomized clinical trial. PLoS ONE. (2015)
10:e0119629. doi: 10.1371/journal.pone.0119629
21. Brave A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, et al.
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral
immune responses by needle-free intradermal delivery. Mol Ther. (2005)
12:1197–205. doi: 10.1016/j.ymthe.2005.06.473
22. Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, Kostic L, et al. Generation
and immunogenicity of novel HIV/AIDS vaccine candidates targeting
HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. (2007) 25:1969–92.
doi: 10.1016/j.vaccine.2006.11.051
23. Gomez CE, Perdiguero B, Jimenez V, Filali-Mouhim A, Ghneim K, Haddad
EK, et al. Systems analysis of MVA-C induced immune response reveals its
significance as a vaccine candidate against HIV/AIDS of clade C. PLoS ONE.
(2012) 7:e35485. doi: 10.1371/journal.pone.0035485
24. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. (2013). MEGA6:
molecular evolutionary genetics analysis version 6.0.Mol Biol Evol. 30:2725–9.
doi: 10.1093/molbev/mst197
25. Saitou N, Nei M. The neighbor-joining method: a new method for
reconstructing phylogenetic trees.Mol Biol Evol. (1987) 4:406–25.
26. Felsenstein J. Confidence limits on phylogenies: an
approach using the bootstrap. Evolution. (1985) 39:783–91.
doi: 10.1111/j.1558-5646.1985.tb00420.x
27. Yu G, Smith DK, Zhu H, Guan Y, Tsan-Yuk Lam T. GGTREE: an r
package for visualization and annotation of phylogenetic trees with their
covariates and other associated data. Methods Ecol Evol. (2017) 8:28–36.
doi: 10.1111/2041-210X.12628
28. Rutten L, Lai YT, Blokland S, Truan D, Bisschop IJM, Strokappe NM,
et al. A universal approach to optimize the folding and stability of
prefusion-closed HIV-1 envelope trimers. Cell Rep. (2018) 23:584–95.
doi: 10.1016/j.celrep.2018.03.061
29. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, et al. Structure
of HIV-1 gp120 with gp41-interactive region reveals layered envelope
architecture and basis of conformational mobility. Proc Natl Acad Sci USA.
(2010) 107:1166–71. doi: 10.1073/pnas.0911004107
30. Kovacs JM, Noeldeke E, Ha HJ, Peng H, Rits-Volloch S, Harrison SC, et al.
Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded
trimer with a native-like structure. Proc Natl Acad Sci USA. (2014) 111:18542–
7. doi: 10.1073/pnas.1422269112
31. Kratochvil S, Mckay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, et al. A
phase 1 human immunodeficiency virus vaccine trial for cross-profiling the
kinetics of serum and mucosal antibody responses to CN54gp140 modulated
by two homologous prime-boost vaccine regimens. Front Immunol. (2017)
8:595. doi: 10.3389/fimmu.2017.00595
32. Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, et al.
Structural constraints determine the glycosylation of HIV-1 envelope trimers.
Cell Rep. (2015) 11:1604–13. doi: 10.1016/j.celrep.2015.05.017
33. Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park SR, et al. Global site-
specific N-glycosylation analysis of HIV envelope glycoprotein.Nat Commun.
(2017) 8:14954. doi: 10.1038/ncomms14954
34. Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong
D, Chantakulkij S, et al. IgG antibody responses to recombinant
gp120 proteins, gp70V1/V2 scaffolds, and a cyclicV2 peptide in
Thai phase I/II vaccine trials using different vaccine regimens.
AIDS Res Hum Retroviruses. (2015) 31:1178–86. doi: 10.1089/aid.201
5.0034
Conflict of Interest Statement: UR and JZ were employed by the company JPT
Peptide Technologies.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Nadai, Held, Joseph, Ahmed, Hoffmann, Peterhoff, Missanga,
Bauer, Joachim, Reimer, Zerweck, McCormack, Cope, Tatoud, Shattock, Robb,
Sandstroem, Hoelscher, Maboko, Bakari, Kroidl, Wagner, Weber, Pollakis and
Geldmacher. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 14 April 2019 | Volume 10 | Article 717
